Fidelity Investments
PBE icon

Fidelity Investments’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Fidelity Investments’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126K Sell
1,407
-17
-1% -$1.4K ﹤0.01% 3870
2026
Q1 		$113K Buy
1,424
+536
+60% +$43.3K ﹤0.01% 3743
2025
Q4 		$73K Buy
888
+421
+90% +$32.6K ﹤0.01% 3915
2025
Q3 		$32.6K Sell
467
-38
-8% -$2.57K ﹤0.01% 4161
2025
Q2 		$32.4K Sell
505
-95
-16% -$5.88K ﹤0.01% 4093
2025
Q1 		$38.1K Sell
600
-67
-10% -$4.51K ﹤0.01% 3975
2024
Q4 		$44.3K Sell
667
-125
-16% -$8.62K ﹤0.01% 3908
2024
Q3 		$55.3K Sell
792
-170
-18% -$11.8K ﹤0.01% 3738
2024
Q2 		$62.4K Buy
962
+724
+304% +$45.8K ﹤0.01% 3501
2024
Q1 		$15.4K Sell
238
-422
-64% -$27.5K ﹤0.01% 4120
2023
Q4 		$43.5K Buy
660
+331
+101% +$19.2K ﹤0.01% 3576
2023
Q3 		$18.8K Sell
329
-366
-53% -$22.3K ﹤0.01% 3841
2023
Q2 		$42.6K Buy
695
+450
+184% +$28.1K ﹤0.01% 3510
2023
Q1 		$15.4K Hold
245
– – ﹤0.01% 3957
2022
Q4 		$15.6K Buy
245
+30
+14% +$1.9K ﹤0.01% 3865
2022
Q3 		$13K Hold
215
– – ﹤0.01% 3992
2022
Q2 		$12K Sell
215
-209
-49% -$12K ﹤0.01% 4063
2022
Q1 		$26K Sell
424
-41
-9% -$2.5K ﹤0.01% 3919
2021
Q4 		$33K Buy
465
+231
+99% +$16.7K ﹤0.01% 3336
2021
Q3 		$18K Buy
234
+144
+160% +$11K ﹤0.01% 3467
2021
Q2 		$7K Hold
90
– – ﹤0.01% 3642
2021
Q1 		$7K Buy
90
+88
+4,400% +$6.66K ﹤0.01% 3479
2020
Q4 		$0 Buy
+2
New +$127 ﹤0.01% 4173
2020
Q1 		– Sell
-101
Closed -$6K – 4083
2019
Q4 		$6K Hold
101
– – ﹤0.01% 3370
2019
Q3 		$5K Buy
101
+100
+10,000% +$5.13K ﹤0.01% 3402
2019
Q2 		$0 Buy
+1
New +$52 ﹤0.01% 4054

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Fidelity Investments's PBE Position: Q2 2026 in Review

Fidelity Investments reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 1.2% in Q2 2026, selling an estimated $1.4K and leaving 1,407 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #3870.

Fidelity Investments first reported a position in PBE in Q2 2019 and has held it in 26 quarters since. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

  • Fidelity Investments held 1,407 shares of Invesco Biotechnology & Genome ETF worth $126K as of Q2 2026.
  • Fidelity Investments sold 17 Invesco Biotechnology & Genome ETF shares in Q2 2026, an estimated $1.4K.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3870 holding.
  • Fidelity Investments first reported a position in Invesco Biotechnology & Genome ETF in Q2 2019 and has held it in 26 quarters since.
  • 105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.